// App-Quantinova.ai

SU-OR35 : 24-Week Interim Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria

Researchers

Presenter

  • Barratt Jonathan

Principal Investigators

  • Tumlin JamesA

  • Suzuki Yusuke

  • Kao Amy

  • Aydemir Aida

  • Zima Yulia

  • Appel GeraldB

Medical Centers

  • University of Leicester, Leicester, Leicestershire, United Kingdom

  • Mercer University School of Medicine, Macon, Georgia, United States

  • Juntendo University, Japan

  • EMD Serono Research Institute Inc. (a business of Merck KGaA Darmstadt Germany) Billerica Massachusetts United States

  • Columbia University, New York, New York, United States

Locations

  • United Kingdom

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

Disease

  • IgA nephropathy

  • Albuminuria

  • Renal disease

Biomarkers

  • Cluster of differentiation 79A

  • Immunoglobulin G

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved